518990-23-3

Basic information

• Product Name: 5-tert-butyl 3-ethyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate
• Synonyms: 5-tert-butyl 3-ethyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate;5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylic acid, 1,4,6,7-tetrahydro-, 5-(1,1-dimethylethyl) 3-ethyl ester;5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylic acid, 1,4,6,7-;5-tert-Butyl 3-ethyl 6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate;1,4,6,7-Tetrahydro-pyrazolo[4,3-c]pyridine-3,5-dicarboxylic acid 5-tert-butyl ester 3-ethyl ester;5-tert-butyl 3-ethyl 1H,4H,5H,6H,7H-pyrazolo[4,3- c]pyridine-3,5-dicarboxylate;5-tert-Butyl 3-ethyl 6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)
• CAS NO: 518990-23-3
• Molecular Formula: C₁₄H₂₁N₃O₄
• Molecular Weight: 296
• Mol File: 518990-23-3.mol

Chemical Properties

• Boiling Point: 484.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.228±0.06 g/cm3(Predicted)
• PKA: 11.85±0.20(Predicted)
• CAS DataBase Reference: 5-tert-butyl 3-ethyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-tert-butyl 3-ethyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate(518990-23-3)
• EPA Substance Registry System: 5-tert-butyl 3-ethyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate(518990-23-3)

Safety Data

• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 518990-23-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-tert-butyl 3-ethyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate is used as a reactant in the preparation of benzimidazoles and their analogs. These compounds have been identified as potential protein kinase inhibitors, which play a crucial role in the regulation of various cellular processes, including cell signaling, growth, and differentiation. By inhibiting specific protein kinases, these benzimidazole derivatives may have therapeutic applications in the treatment of various diseases, such as cancer and inflammatory disorders.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-tert-butyl 3-ethyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate can be utilized as a versatile building block for the development of novel compounds with diverse applications. Its unique structure and functional groups make it a valuable starting material for the synthesis of various organic molecules, including pharmaceuticals, agrochemicals, and advanced materials.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 95-92-1 oxalic acid diethyl ester 
• 518990-24-4 tert-butyl 3-(2-ethoxy-2-oxo-acetyl)-4-oxo-piperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 518990-56-2 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carboxylic acid 
• 1142210-81-8 5-(tert-butyl) 3-ethyl 1-methyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-3,5-dicarboxylate 

Relevant articles and documents

Preparation method of 1, 4, 6, 7-tetrahydro-5H-pyrazolo [4, 3-c] pyridine derivative

The invention relates to a preparation method of a 1, 4, 6, 7-tetrahydro-5H-pyrazolo [4, 3-c] pyridine derivative, and belongs to the technical field of organic synthesis. The preparation method comprises the following steps: constructing a pyrazole ring

NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

Structure-Activity Relationship in Pyrazolo[4,3- c]pyridines, First Inhibitors of PEX14-PEX5 Protein-Protein Interaction with Trypanocidal Activity

Trypanosoma protists are pathogens leading to a spectrum of devastating infectious diseases. The range of available chemotherapeutics against Trypanosoma is limited, and the existing therapies are partially ineffective and cause serious adverse effects. Formation of the PEX14-PEX5 complex is essential for protein import into the parasites' glycosomes. This transport is critical for parasite metabolism and failure leads to mislocalization of glycosomal enzymes, with fatal consequences for the parasite. Hence, inhibiting the PEX14-PEX5 protein-protein interaction (PPI) is an attractive way to affect multiple metabolic pathways. Herein, we have used structure-guided computational screening and optimization to develop the first line of compounds that inhibit PEX14-PEX5 PPI. The optimization was driven by several X-ray structures, NMR binding data, and molecular dynamics simulations. Importantly, the developed compounds show significant cellular activity against Trypanosoma, including the human pathogen Trypanosoma brucei gambiense and Trypanosoma cruzi parasites.

DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS

Provided herein are compounds of formula (I) and (V) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

OXADIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS

Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

PHENOXYMETHYL DERIVATIVES

The invention provides novel compounds having the general formula (I), wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.

DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

PHOSPHODIESTERASE 10 INHIBITORS

Provided are certain quinazolines of formular (I) or (II) that are PDElO inhibitors, pharmaceutical compositions, containing the same and processes for preparing the same. Also provided are methods of treating diseases treatable by PDElO enzyme such as ob